SKIN.SW (Cassiopea S.p.A., SIX) up 9.85% on high volume 13 Jan 2026: Monitor catalyst
The SKIN.SW stock surged 9.85% to CHF 35.70 on 13 Jan 2026 on volume above average, signaling a high-volume mover on the SIX Swiss Exchange. Trading opened at CHF 32.00 and hit a session high of CHF 36.00 before close. Volume reached 2,756 shares versus an average of 1,818, a relative volume of 1.52. This move follows ongoing clinical development updates and thin liquidity that can amplify price swings in biotechnology names.
Market snapshot and session drivers for SKIN.SW stock
Cassiopea S.p.A. (SKIN.SW) closed CHF 35.70 on the SIX in Switzerland on 13 Jan 2026. The one-day change was +CHF 3.20 or +9.85%, with a day range CHF 32.00–36.00 and year range CHF 25.70–53.00. Trade volume of 2,756 exceeded the 50-day average of 1,818, making this a clear high-volume mover.
Catalysts behind the high volume move and SKIN.SW news
Cassiopea is a clinical-stage dermatology biotech with assets such as Winlevi and Breezula in development. Market participants often react to trial updates, licensing chatter, or regulatory news for such stocks. No scheduled earnings announcement was listed, so the jump likely reflects company news flow or sector rotation into healthcare biotech names. For recent corporate details see the company site source.
Fundamentals, valuation and risks for SKIN.SW stock
Recent key metrics show EPS -1.27 and PE -28.13, reflecting negative earnings typical of clinical-stage biotechs. Book value per share is CHF 1.50 and cash per share is CHF 0.25. Price-to-book is elevated at 25.56, highlighting valuation distortion when earnings are negative. Current ratio 1.98 suggests short-term liquidity coverage, but thin free cash flows and small public float raise execution risk.
Technical context and trading dynamics for SKIN.SW stock
The share trades above the 50-day average (CHF 34.37) but below the 200-day average (CHF 37.22). That pattern shows near-term momentum but longer-term downtrend resistance. Relative volume 1.52 amplifies moves; low average daily volume implies that block trades or news can produce outsized swings. Short-term traders should watch day highs CHF 36.00 and support near CHF 32.00.
Meyka AI grade and valuation outlook for SKIN.SW stock
Meyka AI rates SKIN.SW with a score out of 100: 58.75 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst signals and forecasts. The score reflects clinical progress offset by negative earnings, high price-to-book and limited liquidity. These grades are model outputs and are not guaranteed or financial advice.
Forecast scenarios and analyst-style SKIN.SW analysis
Meyka AI’s forecast model projects a base-case price target CHF 42.50 over 12 months. Versus the current CHF 35.70, that implies an upside of 19.05%. A bearish scenario at CHF 28.00 implies downside -21.57%. Forecasts are model-based projections and not guarantees. For updates and company releases see the press page source.
Final Thoughts
SKIN.SW stock posted a notable high-volume gain on 13 Jan 2026, closing at CHF 35.70 after a +9.85% move on the SIX in Switzerland. The session combined above-average volume (2,756) with trade range CHF 32.00–36.00, highlighting short-term interest likely tied to clinical or corporate news. Fundamentals show negative EPS -1.27 and a stretched price-to-book 25.56, which increases valuation risk for longer-term holders. Technicals show support near CHF 32.00 and resistance near the 200-day average CHF 37.22. Meyka AI rates SKIN.SW 58.75/100 (C+, HOLD) and provides a base-case forecast target of CHF 42.50, implying 19.05% upside versus the current price CHF 35.70. Investors should weigh clinical milestones, thin liquidity, and sector volatility before sizing positions. Use the Meyka AI-powered market analysis tools for live alerts and deeper metrics, and monitor company releases on the Cassiopea site and the Meyka stock page for SKIN.SW.
FAQs
What drove the SKIN.SW stock rise on 13 Jan 2026?
The SKIN.SW stock jump of 9.85% was on above-average volume (2,756) and likely tied to clinical or corporate news and thin liquidity that magnifies moves. No formal earnings release was scheduled for the day.
What valuation metrics matter for SKIN.SW stock?
Key metrics: EPS -1.27, PE -28.13, PB 25.56, cash per share CHF 0.25, current ratio 1.98. These show negative earnings and valuation skew due to small float.
What price target does Meyka AI have for SKIN.SW stock?
Meyka AI’s forecast model projects a base-case CHF 42.50, which implies 19.05% upside from the current CHF 35.70. Forecasts are model projections and not guarantees.
How liquid is SKIN.SW stock for traders?
Liquidity is limited: average volume 1,818 and today’s volume 2,756 indicate thin trading. That raises volatility and execution risk for large orders.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
